PROCLAIM: A Phase III Study of Pemetrexed, Cisplatin, and Radiation Therapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiation Therapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Locally Advanced Stage III Non–Small-Cell Lung Cancer of Other than Predominantly Squamous Cell Histology
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference27 articles.
1. Global cancer statistics in the year 2000;Parkin;Lancet Oncol,2001
2. Clinical features of 5,628 primary lung cancer patients: Experience at Mayo Clinic from 1997 to 2003;Yang;Chest,2005
3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials;Non-small Cell Lung Cancer Collaborative Group;BMJ,1995
4. Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC). A meta-analysis using individual patient data from randomised clinical trials;Auperin;J Thorac Oncol,2007
5. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer;Blackstock;J Clin Oncol,2007
Cited by 50 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Optimization of diagnostic and therapeutic management in patients with stage III non-small cell lung cancer — experience of the centers in Poznań;Oncology in Clinical Practice;2023-06-29
2. Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer;Medicine;2019-02
3. Significant Radiation Enhancement Effects by Gold Nanoparticles in Combination with Cisplatin in Triple Negative Breast Cancer Cells and Tumor Xenografts;Radiation Research;2017-02
4. Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat;Oncotarget;2017-01-25
5. Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection;Journal of Thoracic Oncology;2016-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3